ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Altimmune, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$2.23+0.03 (+1.36%)

Close on Oct 19, 2026

Market cap: $413.54M
P/E (TTM): –
Dividend yield: –

Altimmune, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	0.04	0.02	0.43	-0.07	4.41	8.19	5.80	10	11	3.24	–	–	–	–	24	21
Research & Development	66	82	66	71	75	50	18	18	18	7.22	5.13	9.32	15	20	21	21
General & Administrative	28	21	18	17	15	13	8.50	9.77	8.46	7.11	6.22	11	13	12	14	18
Operating Expenses	95	103	96	88	101	63	27	53	63	14	14	20	29	31	36	45
Operating Income	-94	-103	-96	-88	-97	-55	-21	-43	-52	-11	-3.40	-10	-11	-6.27	-12	-24
Interest Expense	1.64	0.01	0.04	0.01	0.01	0.01	0.00	0.30	0.16	0.04	0.05	0.21	0.37	0.32	0.05	5.94
Interest & Investment Income	7.54	8.07	7.35	2.87	0.20	0.32	0.84	0.23	0.05	0.00	–	–	0.00	0.02	0.02	0.01
Other Non-Operating Income	5.72	8.11	7.48	2.83	-0.18	0.34	0.89	-2.49	-0.02	0.00	0.02	0.30	-0.82	1.54	7.93	-11
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	0	2.55	0	0	–	–	–
Asset Impairment Charges	0	0	0	–	11	0	1.00	25	36	–	0.04	–	–	–	–	3.80
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	0.00	-0.01	0.00	0.01	0.01	0.00	0.07	0.78	–
Legal Settlements	–	–	–	–	–	–	–	–	–	217	0	0	–	–	–	–
Pretax Income	-89	-95	-88	-85	-97	-54	-21	-45	-52	-11	-3.38	-9.89	-12	-4.72	-3.80	-35
Income Tax Expense	-0.68	–	–	-0.20	–	-5.42	-0.06	-6.15	-5.64	0	0.06	0.06	0.06	0.20	–	–
Net Income incl. Noncontrolling Interests	-88	-95	-88	-85	-97	-49	-21	-39	-46	–	–	–	–	–	–	–
Net Income	-88	-95	-88	-85	-97	-49	-21	-39	-46	-11	-3.44	-9.96	-12	-4.92	-3.80	-35
Net Income to Common	–	–	–	–	–	-49	-21	-42	-51	-11	–	–	–	–	–	–
EPS (Basic)(per share)	-1.00	-1.34	-1.66	-1.81	-2.35	-1.91	-1.60	-15.16	-118.91	-49.80	-14.00	-47.60	-64.40	-28.00	-22.40	-302.40
EPS (Diluted)(per share)	-1.00	-1.34	-1.66	-1.81	-2.35	-1.91	-1.60	-15.16	-118.91	-49.80	-14.00	-47.60	-64.40	-28.00	-22.40	-302.40
Shares Outstanding (Basic, Weighted)(shares)	88	71	53	47	41	26	13	2.80	0.43	0.23	0.23	0.21	0.18	0.17	0.17	0.12
Shares Outstanding (Diluted, Weighted)(shares)	88	71	53	47	41	26	13	2.80	0.43	0.23	0.23	0.21	0.18	0.17	0.17	0.12
EBITDA	–	–	–	-88	-96	-54	-21	–	–	–	–	–	–	-5.96	-11	-23
Net Interest Income	–	–	–	–	–	–	–	–	–	0.17	-0.05	-0.21	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -244451.2%
Net margin: -223804.9%
Return on equity, FY2025: -50.6%

Financial strength

Current ratio: 26.78
Debt to equity: 0.07
Debt to assets: 6.6%
Cash to current liabilities: 504.0%

Valuation

P/E ratio: –
Price to sales: 10086.33
Price to book: 0.87
Dividend yield: –